3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Uterine Cervical Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
6
Stomach Neoplasms
5
Triple Negative Breast Neoplasms
4
Carcinoma, Renal Cell
4
Advanced Solid Tumors
4
Urinary Bladder Neoplasms
3
Recurrence
3
Pancreatic Neoplasms
3
Melanoma
3
Lung Neoplasms
3
Solid Tumor
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Kidney Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Breast Neoplasms
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Solid Tumors
1
Solid Tumor, Unspecified, Adult
1
Sarcoma
1
Interventions
Everolimus
10
Octreotide
7
pasireotide
5
lanreotide
5
gallium Ga 68 dotatate
4
lutetium Lu 177 dotatate
3
cabozantinib
3
Sunitinib
3
Nivolumab
3
ganitumab
2
Temozolomide
2
Erlotinib Hydrochloride
2
Capecitabine
2
Bevacizumab
2
zimberelimab
1
veliparib
1
telotristat ethyl
1
surufatinib
1
recombinant interferon alpha 2b-like protein
1
pertuzumab
1
pembrolizumab
1
olaparib
1
nintedanib
1
ibrutinib
1
fosbretabulin
1
epothilone B
1
conatumumab
1
cixutumumab
1
carfilzomib
1
azaspirane
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoid Tumor
×
zimberelimab
×
Clear all
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled